Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma

References

• Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol 2011; 104(4):379-85; PMID:21858832; http://dx.doi.org/10.1002/jso.21876
   PubMed Web of Science ®Google Scholar
• Wen DR, Hoon DS, Chang C, Cochran AJ. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol Immunother 1989; 30(5):277-82; PMID:2696592; http://dx.doi.org/10.1007/BF01744894
   PubMed Web of Science ®Google Scholar
• Hoon DS, Bowker RJ, Cochran AJ. Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res 1987; 47(6):1529-33; PMID:2949828
   PubMed Web of Science ®Google Scholar
• Farzad Z, McBride WH, Ogbechi H, Asnong-Holthoff C, Morton DL, Cochran AJ. Lymphocytes from lymph nodes at different distances from human melanoma vary in their capacity to inhibit/enhance tumor cell growth in vitro. Melanoma research 1997; 7(Suppl 2):S59-65; PMID:9578418
   PubMedGoogle Scholar
• Mansfield AS, Holtan SG, Grotz TE, Allred JB, Jakub JW, Erickson LA, Markovic SN. Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol 2011; 4:487-94; PMID:21151098; http://dx.doi.org/10.1038/modpathol.2010.227
   PubMed Web of Science ®Google Scholar
• Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 2009; 15(6):1931-9; PMID:19240164; http://dx.doi.org/10.1158/1078-0432.CCR-08-1980
   PubMed Web of Science ®Google Scholar
• Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4(3):250-5; PMID:11937016; http://dx.doi.org/10.1007/s11912-002-0023-1
   PubMedGoogle Scholar
• Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, Wong P, Wu X, Naidoo J, Page DB et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014; 2(2):127-32; PMID:24778276; http://dx.doi.org/10.1158/2326-6066.CIR-13-0163
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Nevala WK, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology 2013; 2(5):e24436; PMID:23762809; http://dx.doi.org/10.4161/onci.24436
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2(7):632-42; PMID:24838938; http://dx.doi.org/10.1158/2326-6066.CIR-14-0053
   PubMed Web of Science ®Google Scholar
• Sebastiani S, Allavena P, Albanesi C, Nasorri F, Bianchi G, Traidl C, Sozzani S, Girolomoni G, Cavani A. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol 2001; 166(2):996-1002; PMID:11145678; http://dx.doi.org/10.4049/jimmunol.166.2.996
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E, Manes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res 2011; 71(16):5455-66; PMID:21715565; http://dx.doi.org/10.1158/0008-5472.CAN-11-1687
   PubMed Web of Science ®Google Scholar
• Ngai P, McCormick S, Small C, Zhang X, Zganiacz A, Aoki N, Xing Z. Gamma interferon responses of CD4 and CD8 T-cell subsets are quantitatively different and independent of each other during pulmonary Mycobacterium bovis BCG infection. Infect Immun 2007; 75(5):2244-52; PMID:17307945; http://dx.doi.org/10.1128/IAI.00024-07
   PubMed Web of Science ®Google Scholar
• Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007; 4(5):e176; PMID:17488182; http://dx.doi.org/10.1371/journal.pmed.0040176
   PubMed Web of Science ®Google Scholar
• Girard JP, Moussion C, Forster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nature reviews. Immunology 2012; 12(11):762-73; PMID:23018291
   PubMed Web of Science ®Google Scholar
• Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116(7):1757-66; PMID:20143437; http://dx.doi.org/10.1002/cncr.24899
   PubMed Web of Science ®Google Scholar
• Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P, Punt CJ et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 2012; 35(2):169-78; PMID:22306905; http://dx.doi.org/10.1097/CJI.0b013e318247a4e7
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20(19):5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114(8):1537-44; PMID:19423728; http://dx.doi.org/10.1182/blood-2008-12-195792
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26):2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Torisu-Itakura H, Lee JH, Scheri RP, Huynh Y, Ye X, Essner R, Morton DL. Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. Clin Cancer Res 2007; 13(11):3125-32; PMID:17545514; http://dx.doi.org/10.1158/1078-0432.CCR-06-2645
   PubMed Web of Science ®Google Scholar
• Redondo P, Sanchez-Carpintero I, Bauza A, Idoate M, Solano T, Mihm MC, Jr. Immunologic escape and angiogenesis in human malignant melanoma. J Am Acad Dermatol 2003; 49(2):255-63; PMID:12894074; http://dx.doi.org/10.1067/S0190-9622(03)00921-6
   PubMed Web of Science ®Google Scholar
• Kim YS, Choi SJ, Tae YM, Lee BJ, Jeon SG, Oh SY, Gho YS, Zhu Z, Kim YK. Distinct roles of vascular endothelial growth factor receptor-1- and receptor-2-mediated signaling in T cell priming and Th17 polarization to lipopolysaccharide-containing allergens in the lung. J Immunol 2010; 185(9):5648-55; PMID:20921519; http://dx.doi.org/10.4049/jimmunol.1001713
   PubMed Web of Science ®Google Scholar
• Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, Kang MJ, Cohn L, Kim YK, McDonald DM et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nature medicine 2004; 10(10):1095-103; PMID:15378055; http://dx.doi.org/10.1038/nm1105
   PubMed Web of Science ®Google Scholar
• Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, Wu H, Lesinski GB, Kendra K, Chen HX et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007; 14(8):2367-76; PMID:17534686; http://dx.doi.org/10.1245/s10434-007-9389-5
   PubMed Web of Science ®Google Scholar
• Kruijff S, Bastiaannet E, Brouwers AH, Nagengast WB, Speijers MJ, Suurmeijer AJ, Hospers GA, Hoekstra HJ. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma. Ann Surg Oncol 2012; 19(2):620-6; PMID:21861214; http://dx.doi.org/10.1245/s10434-011-2027-2
   PubMed Web of Science ®Google Scholar
• Biswas S, Wrigley J, East C, Hern A, Marshall A, Dunn J, Lorigan P, Middleton M, Corrie P. A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update. Ecancermedicalscience 2008; 2:108; PMID:22275984; http://dx.doi.org/10.3332/ecancer.2008.108
   PubMedGoogle Scholar
• Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70(15):6171-80; PMID:20631075; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153
   PubMed Web of Science ®Google Scholar
• Block MS, Nevala WK, Leontovich AA, Markovic SN. Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shift. Clin Cancer Res 2011; 17(7):1776-83; PMID:21349994; http://dx.doi.org/10.1158/1078-0432.CCR-10-2836
   PubMed Web of Science ®Google Scholar
• Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 2006; 6(9):659-70; PMID:16932751; http://dx.doi.org/10.1038/nri1919
   PubMed Web of Science ®Google Scholar
• Jakub JW, Reintgen DS, Shivers S, Pendas S. Regional node dissection for melanoma: techniques and indication. Surg Oncol Clin N Am 2007; 16(1):247-61; PMID:17336247; http://dx.doi.org/10.1016/j.soc.2006.10.012
   PubMed Web of Science ®Google Scholar